Böhler S, Saubadu S, Scheldewaert R, Figulla H R
Synthélabo Arzneimittel GmbH, Berlin, Germany.
Arzneimittelforschung. 1999 Apr;49(4):311-7. doi: 10.1055/s-0031-1300420.
The use of beta-blockers in heart failure for a long time was regarded as contra-indicated because of their negative inotropic effects. Nevertheless, there is growing evidence that beta-blockers slow down the progression of left ventricular dilatation that characterizes heart failure. In addition changes in left ventricular ejection fraction after several months of beta-blocker treatment appears to have predictive value for survival. This beneficial effect of beta-blockade in chronic heart failure needs to be assessed further. The presumed benefit of beta-blockade with betaxolol (CAS 63659-18-7), a highly selective beta-blocker with long duration of action in chronic heart failure (CHF) will be assessed in BETACAR, a comparative study versus carvedilol (CAS 72956-09-3). The design of this study is provided in this article.
由于其负性肌力作用，β受体阻滞剂长期以来一直被视为心力衰竭的禁忌药物。然而，越来越多的证据表明，β受体阻滞剂可减缓以心力衰竭为特征的左心室扩张进程。此外，经过数月β受体阻滞剂治疗后左心室射血分数的变化似乎对生存具有预测价值。β受体阻滞剂在慢性心力衰竭中的这种有益作用需要进一步评估。在一项与卡维地洛（CAS 72956-09-3）对比的研究BETACAR中，将评估在慢性心力衰竭（CHF）中具有长效作用的高选择性β受体阻滞剂倍他洛尔（CAS 63659-18-7）进行β受体阻滞的假定益处。本文提供了该研究的设计方案。
